简体中文|English
检索试验 按国家、省（市）统计 按疾病代码统计 按试验实施单位统计 按试验主办单位统计 按经费或物资来源统计 按征募研究对象情况统计 按注册状态统计 按干预措施统计 按伦理委员会统计 按研究类型统计
Clinical characteristics and outcomes of cancer patients and their hospital course during the COVID-19 pandemic in a developing country
下载XML文档

注册号：

Registration number：

 ChiCTR2300067424 

最近更新日期：

Date of Last Refreshed on：

 2023-05-12 16:43:49 

注册时间：

Date of Registration：

 2023-01-06 00:00:00 

注册号状态：

补注册

Registration Status：

Retrospective registration

注册题目：

Clinical characteristics and outcomes of cancer patients and their hospital course during the COVID-19 pandemic in a developing country

Public title：

Clinical characteristics and outcomes of cancer patients and their hospital course during the COVID-19 pandemic in a developing country

注册题目简写：

English Acronym：

研究课题的正式科学名称：

Clinical characteristics and outcomes of cancer patients and their hospital course during the COVID-19 infection

Scientific title：

Clinical characteristics and outcomes of cancer patients and their hospital course during the COVID-19 infection

研究课题代号(代码)：

Study subject ID：

在二级注册机构或其它机构的注册号：

The registration number of the Partner Registry or other register：

申请注册联系人：

Muhammad Sohaib Asghar 

研究负责人：

Muhammad Sohaib Asghar 

Applicant：

Muhammad Sohaib Asghar 

Study leader：

Muhammad Sohaib Asghar 

申请注册联系人电话：

Applicant telephone：

 +923343013947

研究负责人电话：

Study leader's
telephone：

+923343013947

申请注册联系人传真 ：

Applicant Fax：

 +923343013947

研究负责人传真：

Study leader's fax：

 +923343013947

申请注册联系人电子邮件：

Applicant E-mail：

 sohaib_asghar123@yahoo.com

研究负责人电子邮件：

Study leader's E-mail：

 sohaib_asghar123@yahoo.com

申请单位网址(自愿提供)：

Applicant website(voluntary supply)：

 https://scholar.google.com/citations?user=qUtKgk4AAAAJ&hl=en

研究负责人网址(自愿提供)：

Study leader's website(voluntary supply)：

 https://www.researchgate.net/profile/Muhammad-Sohaib-Asghar

申请注册联系人通讯地址：

Dow University of Health Sciences

研究负责人通讯地址：

B328, Block-6, Gulshan-e-Iqbal

Applicant address：

Dow University of Health Sciences

Study leader's address：

B328, Block-6, Gulshan-e-Iqbal

申请注册联系人邮政编码：

Applicant postcode：

 75300

研究负责人邮政编码：

Study leader's postcode：

 75300

申请人所在单位：

Dow University of Health Sciences

Applicant's institution：

Dow University of Health Sciences

研究负责人所在单位：

Dow University of Health Sciences

Affiliation of the Leader：

Dow University of Health Sciences

是否获伦理委员会批准：

是

Approved by ethic committee：

Yes

伦理委员会批件文号：

Approved No. of ethic committee：

 IRB/DUH/2021/742021

伦理委员会批件附件：

Approved file of Ethical Committee：

 查看附件View

批准本研究的伦理委员会名称：

Institutional Review Board of Research Department, Dow University of Health Sciences

Name of the ethic committee：

Institutional Review Board of Research Department, Dow University of Health Sciences

伦理委员会批准日期：

Date of approved by ethic committee：

 2021-02-09 00:00:00

伦理委员会联系人：

Amanullah Abbasi

Contact Name of the ethic committee：

Amanullah Abbasi

伦理委员会联系地址：

Dow University of Health Sciences, Suparco Road, Scheme 33, Karachi, Pakistan. 74233.

Contact Address of the ethic committee：

Dow University of Health Sciences, Suparco Road, Scheme 33, Karachi, Pakistan. 74233.

伦理委员会联系人电话：

Contact phone of the ethic committee：

 +922132745827

伦理委员会联系人邮箱：

Contact email of the ethic committee：

 info@duhs.edu.pk

研究实施负责（组长）单位：

none

Primary sponsor：

none

研究实施负责（组长）单位地址：

none

Primary sponsor's address：

none

试验主办单位(项目批准或申办者)：

Secondary sponsor：

国家：

Not stated

省(直辖市)：

Not stated

市(区县)：

Country：

Not stated

Province：

Not stated

City：

单位(医院)：

Not stated

具体地址：

Not stated

Institution
hospital：

Not stated

Address：

Not stated

经费或物资来源：

None

Source(s) of funding：

None

研究疾病：

COVID-19  

Target disease：

COVID-19

研究疾病代码：

Target disease code：

研究类型：

观察性研究

Study type：

Observational study

研究所处阶段：

 回顾性研究 

Study phase：

Retrospective study

研究设计：

队列研究 

Study design：

Cohort study 

研究目的：

We aimed to compare the type and magnitude of COVID-19 clinical manifestations among cancer patients in our center to non-cancer COVID-19 affected patients.  

Objectives of Study：

We aimed to compare the type and magnitude of COVID-19 clinical manifestations among cancer patients in our center to non-cancer COVID-19 affected patients.

药物成份或治疗方案详述：

 

Description for medicine or protocol of treatment in detail：

 

纳入标准：

Inclusion criteria

排除标准：

Those patients who were managed outpatient or were suspected cases of COVID-19 but their PCT returned negative were excluded from the study.

Exclusion criteria：

Those patients who were managed outpatient or were suspected cases of COVID-19 but their PCT returned negative were excluded from the study.

研究实施时间：

Study execute time：

从 From 2020-03-08 00:00:00至 To 2020-10-26 00:00:00  

征募观察对象时间：

Recruiting time：

从 From 2020-03-08 00:00:00 至 To 2020-10-26 00:00:00

干预措施：

Interventions：

组别：

non-cancer patients

样本量：

 71

Group：

non-cancer patients

Sample size：

干预措施：

COVID-19 positive

干预措施代码：

Intervention：

COVID-19 positive

Intervention code：

组别：

cancer patients

样本量：

 28

Group：

cancer patients

Sample size：

干预措施：

COVID-19 positive

干预措施代码：

Intervention：

COVID-19 positive

Intervention code：

研究实施地点：

Countries of recruitment and research settings：

国家：

 Pakistan

省(直辖市)：

 Sindh 

市(区县)：

 Karachi 

Country：

Pakistan

Province：

Sindh

City：

Karachi

单位(医院)：

 Dow University Hospital 

单位级别：

 Tertiary care 

Institution
hospital：

Dow University Hospital

Level of the institution：

Tertiary care

测量指标：

Outcomes：

指标中文名：

Disease course

指标类型：

主要指标

Outcome：

Disease course

Type：

Primary indicator

测量时间点：

测量方法：

Measure time point of outcome：

Measure method：

指标中文名：

Laboratory markers

指标类型：

次要指标

Outcome：

Laboratory markers

Type：

Secondary indicator

测量时间点：

测量方法：

Measure time point of outcome：

Measure method：

指标中文名：

Signs and symptoms

指标类型：

附加指标

Outcome：

Signs and symptoms

Type：

Additional indicator

测量时间点：

测量方法：

Measure time point of outcome：

Measure method：

指标中文名：

Death

指标类型：

附加指标

Outcome：

Death

Type：

Additional indicator

测量时间点：

测量方法：

Measure time point of outcome：

Measure method：

采集人体标本：

Collecting sample(s)
from participants：

标本中文名：

COVID-19 PCR

组织：

Nasopharyngeal swab

Sample Name：

COVID-19 PCR

Tissue：

Nasopharyngeal swab

人体标本去向

 其它  

说明

Fate of sample：

0thers  

Note：

征募研究对象情况：

Recruiting status：

结束

/Completed

年龄范围：

Participant age：
最小 Min age 18 岁 years
最大 Max age 80 岁 years

性别：

男女均可

Gender：

Both

随机方法（请说明由何人用什么方法产生随机序列）：

Not applicable

Randomization Procedure (please state who generates the random number sequence and by what method)：

Not applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法：

Blinding：

试验完成后的统计结果（上传文件）：

Calculated Results after
the Study Completed(upload file)：

是否共享原始数据：

IPD sharing

否No

共享原始数据的方式（说明：请填入公开原始数据日期和方式，如采用网络平台，需填该网络平台名称和网址）：

All data associated with this research can be accessed via emailing the corresponding author. Currently data is not made available to any repository.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url)：

All data associated with this research can be accessed via emailing the corresponding author. Currently data is not made available to any repository.

数据采集和管理（说明：数据采集和管理由两部分组成，一为病例记录表(Case Record Form, CRF)，二为电子采集和管理系统(Electronic Data Capture, EDC)，如ResMan即为一种基于互联网的EDC：

No standard protocols were made available online for the dissemination of data collection and management. All data were captured through the electronic medical records of the study participants.

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture：

No standard protocols were made available online for the dissemination of data collection and management. All data were captured through the electronic medical records of the study participants.

数据与安全监察委员会：

Data and Safety Monitoring Committee：

暂未确定/Not yet

注册人：

Name of Registration：

  2023-01-06 17:49:36
返回列表
欢迎访问WHO国际临床试验注册平台 Clinical Trials Hong Kong

中国临床试验注册中心 - 世界卫生组织国际临床试验注册平台一级注册机构

Copyright(c) (2005 - 2023) Chictr.org.cn.All rights reserved. 中国临床试验注册中心 版权所有

蜀ICP备16010396号-9

提示：推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统